|1.||Muchmore, Douglas B: 4 articles (03/2012 - 07/2007)|
|2.||Milicevic, Zvonko: 4 articles (09/2009 - 01/2002)|
|3.||Holcombe, John H: 3 articles (05/2014 - 12/2004)|
|4.||Campaigne, B N: 3 articles (09/2003 - 02/2000)|
|5.||Arora, V: 3 articles (09/2003 - 02/2000)|
|6.||Zinman, B: 3 articles (12/2001 - 01/2000)|
|7.||Mamza, J: 2 articles (03/2015 - 01/2014)|
|8.||Idris, I: 2 articles (03/2015 - 01/2014)|
|9.||Rees, Tina M: 2 articles (03/2015 - 05/2014)|
|10.||Starup-Linde, Jakob: 2 articles (01/2015 - 11/2013)|
|1.||Type 1 Diabetes Mellitus (Autoimmune Diabetes)
05/01/1999 - "Long-term efficacy of humalog in subjects with Type 1 diabetes mellitus."
08/01/1997 - "Strategies toward improved control during insulin lispro therapy in IDDM. "
03/01/1997 - "Prolonged efficacy of short acting insulin Lispro in combination with human ultralente in insulin-dependent diabetes mellitus."
09/01/2008 - "We simulate pulsatile implementations of a basal rate profile over a day on a type 1 diabetes mellitus patient using insulin lispro. "
11/01/2002 - "Insulin lispro therapy in pregnancies complicated by type 1 diabetes mellitus."
|2.||Hypoglycemia (Reactive Hypoglycemia)
05/01/2012 - "In the RCTs, severe hypoglycemia rates of 0.1 to 0.3 episodes/patient per year were reported for insulin lispro CSII therapy; those trials with MDI comparator arms reported relatively similar severe hypoglycemia rates (0.1 to 0.5 episodes/patient per year). "
01/01/2015 - "Additionally, the 1:1 ratio of Humalog Mix 50/50 showed a trend towards fewer episodes of nocturnal hypoglycemia. "
09/07/2014 - "Without a nutritional source, Lispro worsened GV through frequent hypoglycemia episodes as the injection dose increased. "
05/01/2014 - "Obese patients with T2DM treated with insulin lispro were able to achieve the same level of glycemic control as their nonobese counterparts, with some evidence supporting a reduced risk of hypoglycemia."
05/01/2012 - "Where reported, insulin lispro CSII and MDI therapy demonstrated a similar occurrence of DKA and incidence of severe hypoglycemia. "
|3.||Type 2 Diabetes Mellitus (MODY)
10/01/1999 - "This study assessed the safety profile and efficacy of a new combination therapy (insulin lispro plus sulfonylurea) in patients with type 2 diabetes mellitus experiencing secondary oral agent failure. "
02/01/2000 - "Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus."
06/09/1997 - "The efficacy of insulin lispro in the clinical therapy of patients with non-insulin-dependent diabetes mellitus (NIDDM) has not been tested. "
12/01/2014 - "A Randomized Trial of Step-up Treatment with Premixed Insulin Lispro-50/50 vs. Aspart-70/30 in Patients with Type 2 Diabetes Mellitus."
11/01/2014 - "[Efficacy and safety of insulin lispro in obese patients with type 2 diabetes mellitus: a retrospective metaanalysis of 7 randomized controlled trials]."
03/01/2008 - "These findings suggest that insulin lispro could be useful for the treatment of hyperglycemia in type 1 diabetic pregnant women."
09/07/2014 - "With continuous enteral feeds and borderline to mild IR, Lispro showed minimal effect on GV; however, rebound hyperglycemia that increased GV occurred when the IR was moderate to high. "
05/01/2005 - "In women with gestational diabetes mellitus (GDM), the use of insulin lispro is efficient in reducing postprandial hyperglycemia and some neonatal features related to hyperglycemia, thus stressing its usefulness in this condition. "
01/01/1999 - "In 48 randomized overnight studies, 12 healthy adult type 1 diabetic patients received lispro insulin 0.15 U/kg admixed with human ultralente 0.2 U/kg (as background insulin) subcutaneously at minutes (-30, -15, 0, and +15) relative to the ingestion of an American Diabetes Association breakfast of 8.6 kcal/kg. Pre-breakfast hyperglycemia of 10.2 +/- 0.2 mmol/l was established before the study by continuous overnight infusion of intravenous insulin, which was stopped 30 min before lispro insulin injection. "
12/01/1996 - "The more rapid action of lispro is an advantage in the correction of hyperglycemia, even though actual differences in glucose concentrations are smaller than suggested by previous clamped studies."
|5.||Diabetic Ketoacidosis (Ketoacidosis, Diabetic)
09/01/2013 - "Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: a review of the current evidence from clinical studies."
03/01/2010 - "Insulin lispro is an ultrashort-acting analog that has been used in the intensive treatment of dogs with diabetic ketoacidosis. "
01/01/2005 - "Treatment of diabetic ketoacidosis with subcutaneous insulin lispro."
09/01/2004 - "Treatment of diabetic ketoacidosis in the intensive care unit was associated with 39% higher hospitalization charges than was treatment with subcutaneous lispro in a non-intensive care setting ($14,429 +/- $5243 vs. $8801 +/- $5549, P <0.01). "
04/01/2006 - "Subcutaneous lispro and intravenous regular insulin treatments are equally effective and safe for the treatment of mild and moderate diabetic ketoacidosis in adult patients."
|2.||insulin aspart (NovoLog)
|4.||Blood Glucose (Blood Sugar)
|5.||glargine (insulin glargine)